In an older adult with an osteoporotic vertebral compression fracture and no recent cardiovascular disease, how do teriparatide (recombinant parathyroid hormone) and romosozumab (sclerostin inhibitor) differ in mechanism, dosing schedule, treatment duration, safety profile, and need for subsequent anti‑resorptive therapy?

Teriparatide vs Romosozumab: Key Differences

For an older adult with an osteoporotic vertebral compression fracture and no recent cardiovascular disease, romosozumab offers superior bone density gains and faster fracture risk reduction compared to teriparatide, but requires monthly injections for only 12 months versus daily injections for up to 24 months with teriparatide.

Mechanism of Action

Teriparatide is a recombinant parathyroid hormone analog (PTH 1-34) that works as a pure anabolic agent, stimulating bone formation when administered intermittently through daily subcutaneous injections 1. It binds to PTH1 receptors on osteoblasts, increasing bone formation primarily through remodeling-based mechanisms 2.

Romosozumab is a monoclonal antibody that blocks sclerostin binding to osteoblasts, producing a dual effect: it simultaneously increases bone formation and decreases bone resorption 2. This dual mechanism results in dramatic bone density increases through both modeling (increased cross-sectional area) and remodeling (bone repair) 2.

Dosing Schedule & Treatment Duration

Teriparatide

• Dose: 20 mcg subcutaneously daily 1
• Duration: Up to 2 years maximum during a patient's lifetime 2
• Requires refrigeration initially; patients must self-inject every day 2
• Initial doses should be given where patient can sit/lie down due to orthostatic hypotension risk 1

Romosozumab

• Dose: 210 mg subcutaneously monthly 2
• Duration: 12 months only 2
• Much shorter treatment window but more convenient dosing frequency
• Can potentially be used after teriparatide or retreated in future 2

Efficacy Comparison

Romosozumab demonstrates superior bone density gains in head-to-head studies:

• Lumbar spine BMD: Romosozumab increased 9.8% vs teriparatide 5.4% at 12 months in patients previously on bisphosphonates 2
• Total hip BMD: Romosozumab increased 2.9% vs teriparatide -0.5% 2
• Femoral neck BMD: Romosozumab increased 3.2% vs teriparatide -0.2% 2

In QCT studies, romosozumab produced greater gains in total spine (17.7% vs 12.9%) and total hip (4.1% vs 1.2%) volumetric BMD compared to teriparatide 2.

Fracture reduction: Both agents significantly reduce vertebral and nonvertebral fractures. Romosozumab showed 73% vertebral fracture reduction vs placebo and 34% reduction vs alendronate at 12 months 2. Teriparatide showed 74% vertebral fracture reduction and 39% nonvertebral fracture reduction vs placebo 3.

Safety Profile

Teriparatide

• Boxed warning (recently removed but still relevant): Osteosarcoma risk in rats at high doses; avoid in patients with Paget's disease, open epiphyses, prior skeletal radiation, bone metastases, or hereditary disorders predisposing to osteosarcoma 2, 1
• Common side effects: Nausea, orthostatic hypotension (usually with first few doses), leg cramps 2
• Hypercalcemia: Mild, transient, uncommon; measure calcium ≥16 hours after injection 2, 1
• Contraindicated in untreated hyperparathyroidism 2, 1
• Can be used in patients with prior radiation exposure 1

Romosozumab

• Black-box warning: Increased cardiovascular events vs alendronate in one trial; contraindicated in patients with recent MI or stroke or high cardiovascular risk 2
• This is the critical safety distinction for your patient without recent cardiovascular disease—romosozumab is appropriate
• Can be used in patients with prior radiation exposure (unlike teriparatide restrictions) 2
• Risk of calciphylaxis and worsening cutaneous calcification reported 1

Need for Subsequent Anti-Resorptive Therapy

Both agents absolutely require sequential anti-resorptive therapy—this is non-negotiable 2.

After Teriparatide

• Bone density declines quickly within the following year if not followed by anti-resorptive therapy 2
• Must transition immediately to bisphosphonate or denosumab—no "washout period" or "drug holiday" needed 2
• Fracture reduction may persist 1-2 years even without follow-up therapy, but BMD gains are lost 2

After Romosozumab

• All major trials transitioned patients to denosumab or alendronate after 12 months 2
• Sequential therapy maintained and enhanced BMD gains 2
• The 12-month romosozumab followed by denosumab showed 75% vertebral fracture reduction at 24 months 2

Prior Bisphosphonate Use Considerations

Critical caveat: Both agents show "blunted" responses in patients previously treated with bisphosphonates, though they remain effective 2, 3.

• Teriparatide: BMD and bone turnover marker changes are attenuated but fracture efficacy is preserved in prior bisphosphonate users 3
• Romosozumab: Still showed superior BMD gains vs teriparatide even in patients with mean 6.2 years of prior bisphosphonate therapy 2
• Treatment-naïve patients derive the greatest benefit from both agents 4

Important: Switching from denosumab to teriparatide causes BMD decrease for 6-12 months—not advisable 2. However, teriparatide can be added to ongoing denosumab therapy 2.

Clinical Decision Algorithm for Your Patient

For an older adult with osteoporotic vertebral compression fracture and no recent cardiovascular disease:

1. First-line choice: Either agent is appropriate, but romosozumab offers:

   • Faster, more dramatic BMD gains (especially at hip)
   • More convenient monthly dosing vs daily injections
   • Shorter treatment duration (12 vs 24 months)
   • Dual mechanism (formation + anti-resorption)

2. Choose teriparatide if:

   • Patient has cardiovascular disease or high CV risk
   • Prior skeletal radiation (relative consideration)
   • Patient prefers potentially longer anabolic window (up to 24 months)
   • Cost/insurance coverage favors teriparatide

3. Choose romosozumab if:

   • Patient is treatment-naïve or has limited prior bisphosphonate exposure
   • Rapid BMD gains are priority (severe osteoporosis)
   • Patient prefers monthly vs daily injections
   • No cardiovascular contraindications

4. After completing either agent: Immediately transition to denosumab (preferred based on trial data) or bisphosphonate—no gap in therapy 2.

Common Pitfalls to Avoid

• Never stop anabolic therapy without immediate anti-resorptive follow-up—BMD gains will be lost 2
• Do not switch from denosumab to teriparatide—causes rebound bone loss 2
• Do not use romosozumab in patients with recent MI, stroke, or high CV risk—black-box warning 2
• Do not exceed 2 years lifetime teriparatide use unless patient returns to very high fracture risk 2, 1
• Do not use teriparatide in patients with unexplained elevated alkaline phosphatase—rule out Paget's disease first 2, 1